Behavioral studies of mice with breast cancer after treatment with new anticancer agent, Rh2-containing arginine-graphene

Objectives: Ginsenoside Rh2-containing arginine-reduced graphene (Gr-Arg-Rh2) is a new designed anticancer nondrug for treatment of cancer. In this study, behavior of mice with breast cancer was evaluated after treatment with Gr-Arg-Rh2. Methods: Thirty-two cancerous mice were divided into 4 groups and treated every three days for a duration of 32 days: Group 1, PBS: 60 mu l (6 mg/kg), Group 2, Rh2: 60 mu l (6 mg/kg), Group 3, Gr-Arg: 70 mu l (3 mg/kg), and Group 4, Gr-Arg-Rh2: 70 mu l (3 mg/kg). Behavioral demonstrations were assessed following the treatment. Results: Results showed that the mice treated with the Gr-Arg and Gr-Arg-Rh2 appeared to be more energetic than Rh2 and control groups. Conclusions: Based on the results, Gr-Arg-Rh2 can reduce cancer-related fatigue and low energy in cancerous patients.